Auph short interest.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 16.4% in August marketbeat.com - September 17 at 6:15 AM: Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation finance.yahoo.com - September 11 at 9:56 AMPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of FloatMar 7, 2022 · The actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ... Aurinia Pharmaceuticals (AUPH) traded ~5% higher pre-market Thursday after the co. raised its outlook and posted better-than-expected Q2 2023 financials. Read more here.

Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...View the basic AUPH option chain and compare options of Aurinia Pharmaceuticals Inc. on Yahoo Finance. ... Open Interest Implied Volatility; AUPH231215P00005000: 2023-11-15 12:00PM EST: 5.00: 0.04 ...WebAurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...

The forecasted annual EBITDA of AUPH / Aurinia Pharmaceuticals Inc in 2025-12-31 is -52MM. EBIDTA is an acronym that stands for earnings before interest, taxes, depreciation, and amortization. Analysts and investors pay attention to EBITDA because it strips out items that a company must report on its balance sheet but doesn’t significantly ...

Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ...Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...

Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...

Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...

Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ...Biogen has more recently been seen as a potential acquirer of AUPH after a Stat News report said that Biogen is working with Goldman Sachs to find potential targets for the company. Aurinia ( AUPH ...AUPH | Aurinia Pharmaceuticals by Finance Ai provides AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report with insider trading history and institutional ownership breakdown.Financials. AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of ...Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...

Short Squeeze - Canada; Short Squeeze - Hong Kong; Highest Cost to Borrow; Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium …WebNov 24, 2023 · Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value. A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Short Interest ...On another thread there us a guy who is misguided and blaming mgmt. Claims short interest is going up. I checked itsv8.5% as of May 15th. We should soon find out if short interest has gone up.AuriniaPharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 12,670,00Web

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) d

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 16.4% in August marketbeat.com - September 17 at 6:15 AM: Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation finance.yahoo.com - September 11 at 9:56 AMDec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents. Sep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHApproximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interestAurinia Pharmaceuticals ( NASDAQ: AUPH) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH) surged 38% on ...

Aptevo Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 26,900 shares, a decline of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the short-interest ratio is currently 0.1 days. View Aptevo Therapeutics' Short …

Short interest, stock short squeeze, short interest ratio & short selling data positions for NASDAQ, NYSE & AMEX stocks to find shorts in the stock market.Web

2023-03-14 Short sale volume (not short interest) for $AUPH is 32%. http://shortvolumes.com/?t=AUPH $XLV 48% $AEZS 50% $REGN 54%. 16 Mar 2023 00:36:01WebThe actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ...Biogen has more recently been seen as a potential acquirer of AUPH after a Stat News report said that Biogen is working with Goldman Sachs to find potential targets for the company. Aurinia ( AUPH ...Today's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Apr 24, 2023 · MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ... Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQAurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …Mar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ... The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an …A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Short Interest ...

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia …Jan 5, 2023 · AUPH has multiple downside risks that investors need to consider when managing their position. First, Aurinia is still recording losses and reported a net loss of $82.1M for the first three ... Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...Instagram:https://instagram. lockheeed martin stocknyse chipotlewhich schwab fund is bestvcr vanguard Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin ... dow stock dividendpolaris electric utility vehicle These cookies may be set through our site by us and our advertising partners to make advertising messages more relevant to you. They perform functions like preventing the same ad from continuously reappearing, ensuring that ads are properly displayed for advertisers, selecting advertisements that are based on your interests and measuring the number of …“The possibility of a short squeeze is one reason some analysts look at a high amount of short interest as a bullish indicator. Short Interest is the fuel, performance is the fuse, says ShortSqueeze.com” - USA Today ...short sellers, not financial results, are driving up … best stock information app Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... About Aurinia Pharmaceuticals Stock (TSE:AUP) Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license ...AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet;